Rajendiran Smrithi, Maji Sayantan, Haddad Ahmed, Lotan Yair, Nandy Rajesh R, Vishwanatha Jamboor K, Chaudhary Pankaj
Department of Microbiology, Immunology, and Genetics, University of North Texas Health Science Center, Fort Worth, TX, United States.
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Front Oncol. 2021 Mar 19;11:628094. doi: 10.3389/fonc.2021.628094. eCollection 2021.
Prostate cancer is one of the leading causes of death despite an astoundingly high survival rate for localized tumors. Though prostate specific antigen (PSA) test, performed in conjunction with digital rectal examinations, is reasonably accurate, there are major caveats requiring a thorough assessment of risks and benefits prior to conducting the test. MicroRNAs, a class of small non-coding RNAs, are stable molecules that can be detected in circulation by non-invasive methods and have gained importance in cancer prognosis and diagnosis in the recent years. Here, we investigate circulating miR-940, a miRNA known to play a role in prostate cancer progression, in both cell culture supernatants as well as patient serum and urine samples to determine the utility of miR-940 as a new molecular marker for prostate cancer detection. We found that miR-940 was significantly higher in serum from cancer patients, specifically those with clinically significant tumors (GS ≥ 7). Analysis of receiver operating characteristic curve demonstrated that miR-940 in combination with PSA had a higher area under curve value (AUC: 0.818) than the miR-940 alone (AUC: 0.75) for the diagnosis of prostate cancer. This study provides promising results suggesting the use of miR-940 for prostate cancer diagnosis.
尽管局限性前列腺癌的生存率高得惊人，但前列腺癌仍是主要的死亡原因之一。虽然结合直肠指检进行的前列腺特异性抗原（PSA）检测相当准确，但在进行该检测之前，仍有一些重大注意事项需要对风险和益处进行全面评估。微小RNA（MicroRNAs）是一类小的非编码RNA，是稳定的分子，可通过非侵入性方法在循环中检测到，近年来在癌症预后和诊断中变得越来越重要。在这里，我们在细胞培养上清液以及患者血清和尿液样本中研究循环miR-940（一种已知在前列腺癌进展中起作用的微小RNA），以确定miR-940作为前列腺癌检测新分子标志物的效用。我们发现，癌症患者血清中的miR-940显著更高，特别是那些患有具有临床意义肿瘤（GS≥7）的患者。受试者工作特征曲线分析表明，对于前列腺癌的诊断，miR-940与PSA联合使用时的曲线下面积值（AUC：0.818）高于单独使用miR-940时（AUC：0.75）。这项研究提供了有希望的结果，表明miR-940可用于前列腺癌诊断。
